Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Goldblatt

Showing results (201-210 of 242) with videos related to

Pageof 25
Sort By:
The Lancet. Infectious Diseases|August 29, 2020
Immunogenicity of a single-dose compared with a two-dose primary series followed by a booster dose of ten-valent or 13-valent pneumococcal conjugate vaccine in South African children: an open-label, randomised, non-inferiority trialShabir A Madhi, Eleonora Aml Mutsaerts, Alane Izu, et al.
The Lancet. Infectious Diseases|January 13, 2023
Immunogenicity and safety of a 10-valent pneumococcal conjugate vaccine administered as a 2 + 1 schedule to healthy infants in The Gambia: a single-centre, double-blind, active-controlled, randomised, phase 3 trialIkechukwu Adigweme, Ahmed Futa, Ebrima Saidy-Jah, et al.
The Journal of Infectious Diseases|December 31, 2016
Association of Pneumococcal Protein Antigen Serology With Age and Antigenic Profile of Colonizing IsolatesTaj Azarian, Lindsay R Grant, Maria Georgieva, et al.
Vaccine|December 22, 2021
Towards a population-based threshold of protection for COVID-19 vaccinesDavid Goldblatt, Andrew Fiore-Gartland, Marina Johnson, et al.
Journal of Human Immunity|May 22, 2026
Beyond survival: Multisystem long-term outcomes following HSCT in chronic granulomatous diseaseValentina Guarnieri, Jesmeen Maimaris, Sohilla Lotfy, et al.
Vaccine|April 12, 2023
Pneumococcal carriage following PCV13 delivered as one primary and one booster dose (1 + 1) compared to two primary doses and a booster (2 + 1) in UK infantsDavid Goldblatt, Nick J Andrews, Carmen L Sheppard, et al.
The Lancet. Infectious Diseases|August 27, 2022
Waning of antibody levels induced by a 13-valent pneumococcal conjugate vaccine, using a 3 + 0 schedule, within the first year of life among children younger than 5 years in Blantyre, Malawi: an observational, population-level, serosurveillance studyTodd D Swarthout, Marc Y R Henrion, Deus Thindwa, et al.
Vaccine|February 13, 2024
Immunization with a whole cell vaccine reduces pneumococcal nasopharyngeal density and shedding, and middle ear infection in miceJayne Manning, Sam Manna, Eileen M Dunne, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 17, 2015
Antibody responses after primary immunization in infants born to women receiving a pertussis-containing vaccine during pregnancy: single arm observational study with a historical comparatorShamez N Ladhani, Nick J Andrews, Jo Southern, et al.
Scientific Reports|May 20, 2022
Transmission dynamics of SARS-CoV-2 in a strictly-Orthodox Jewish community in the UKWilliam Waites, Carl A B Pearson, Katherine M Gaskell, et al.
Pageof 25

Showing results (201-210 of 242) with videos related to

Sort By:
Pageof 25
The Lancet. Infectious Diseases|August 29, 2020
Immunogenicity of a single-dose compared with a two-dose primary series followed by a booster dose of ten-valent or 13-valent pneumococcal conjugate vaccine in South African children: an open-label, randomised, non-inferiority trialShabir A Madhi, Eleonora Aml Mutsaerts, Alane Izu, et al.
The Lancet. Infectious Diseases|January 13, 2023
Immunogenicity and safety of a 10-valent pneumococcal conjugate vaccine administered as a 2 + 1 schedule to healthy infants in The Gambia: a single-centre, double-blind, active-controlled, randomised, phase 3 trialIkechukwu Adigweme, Ahmed Futa, Ebrima Saidy-Jah, et al.
The Journal of Infectious Diseases|December 31, 2016
Association of Pneumococcal Protein Antigen Serology With Age and Antigenic Profile of Colonizing IsolatesTaj Azarian, Lindsay R Grant, Maria Georgieva, et al.
Vaccine|December 22, 2021
Towards a population-based threshold of protection for COVID-19 vaccinesDavid Goldblatt, Andrew Fiore-Gartland, Marina Johnson, et al.
Journal of Human Immunity|May 22, 2026
Beyond survival: Multisystem long-term outcomes following HSCT in chronic granulomatous diseaseValentina Guarnieri, Jesmeen Maimaris, Sohilla Lotfy, et al.
Vaccine|April 12, 2023
Pneumococcal carriage following PCV13 delivered as one primary and one booster dose (1 + 1) compared to two primary doses and a booster (2 + 1) in UK infantsDavid Goldblatt, Nick J Andrews, Carmen L Sheppard, et al.
The Lancet. Infectious Diseases|August 27, 2022
Waning of antibody levels induced by a 13-valent pneumococcal conjugate vaccine, using a 3 + 0 schedule, within the first year of life among children younger than 5 years in Blantyre, Malawi: an observational, population-level, serosurveillance studyTodd D Swarthout, Marc Y R Henrion, Deus Thindwa, et al.
Vaccine|February 13, 2024
Immunization with a whole cell vaccine reduces pneumococcal nasopharyngeal density and shedding, and middle ear infection in miceJayne Manning, Sam Manna, Eileen M Dunne, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 17, 2015
Antibody responses after primary immunization in infants born to women receiving a pertussis-containing vaccine during pregnancy: single arm observational study with a historical comparatorShamez N Ladhani, Nick J Andrews, Jo Southern, et al.
Scientific Reports|May 20, 2022
Transmission dynamics of SARS-CoV-2 in a strictly-Orthodox Jewish community in the UKWilliam Waites, Carl A B Pearson, Katherine M Gaskell, et al.
Pageof 25